

POLICY STEERING GROUP FOR THE REDEVELOPMENT OF BPL

AGENDA ITEM 3a.

MANUFACTURE OF PRODUCTS BY GENETIC ENGINEERING

At the last meeting of the PSG it was asked whether the redeveloped BPL would be permitted to produce genetically engineered material in direct competition with Industry. As a general principle Ministers are not in favour of NHS facilities engaging in activities which Industry is competent to perform. This does not preclude involvement in product development but, with certain exceptions (eg products derived from human substances) manufacture of products which are or will be available commercially is difficult to justify.

Secretariat

NOT FOR PUBLICATION

2249

JOINT MANAGEMENT COMMITTEE (DHSS/NW THAMES RHA) FOR THE CENTRAL BLOOD LABORATORIES - POLICY STEERING GROUP FOR THE REDEVELOPMENT OF THE BLOOD PRODUCTS LABORATORY

Second meeting to be held on 30 September 1981 at 2 00pm in room 87, Hannibal House, Elephant and Castle, London SE1.

AGENDA

1. Apologies for absence.
2. Minutes of first meeting - PSG 81/7 already circulated.
3. Matters arising:
 - a. manufacture of products by genetic engineering - PSG 81/10 to follow.
 - b. plasma supply -
4. Preliminary consideration of architect's brief
5. (a) Arrangements for project management - PSG 81/9 attached.
(b) [if appropriate] arrangements to appoint a project manager.
6. Involvement of staff at BPL.
7. Any other business.
8. Date of next meeting.

Secretariat